Jaguar Health, Inc. (NASDAQ:JAGX) | Finanzwire

Basculer en Français

10053	Companies
205214	Keywords
135460	Articles
108805	Press releases

Home
Companies
Jaguar Health, Inc.

BRIEF

published on 05/20/2025 at 15:20, 9 months 29 days ago

Jaguar Health Begins Phase 2 Trial for Crofelemer in Pediatric MVID Patients

Crofelemer Jaguar Health Phase 2 Trial MVID Pediatric Treatment
PRESS RELEASE

published on 05/20/2025 at 15:15, 9 months 29 days ago

First Patient Randomized in Jaguar Health’s Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease (MVID)
Jaguar Health's crofelemer shows promise in reducing total parenteral support in pediatric MVID patient. Ongoing trials and future expectations discussed

Crofelemer Clinical Trials Jaguar Health Pediatric MVID Total Parenteral Support
BRIEF

published on 05/19/2025 at 16:42, 9 months 30 days ago

Jaguar Health Inc Receives Buy Rating from First Berlin Equity Research

Crofelemer FDA Approval BUY Rating Jaguar Health Growth Potential
PRESS RELEASE

published on 05/19/2025 at 16:37, 9 months 30 days ago

Original-Research: Jaguar Health Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research initiates coverage on Jaguar Health Inc, recommending a Buy with USD 60.00 price target. Jaguar focuses on plant-based medicines for GI health challenges, with crofelemer as flagship product

Jaguar Health Inc First Berlin Equity Research BUY Rating Plant-based Medicines GI Health Challenges
BRIEF

published on 05/15/2025 at 20:35, 10 months 3 days ago

Jaguar Health Reports Decreased Revenue in Q1 2025

Revenue Decline Prescription Products FDA Meeting Q1 2025 Financials Mytesi Growth
PRESS RELEASE

published on 05/15/2025 at 20:30, 10 months 3 days ago

Jaguar Health Reports First Quarter 2025 Financials
Jaguar Health, Inc. reports Q1 2025 financial results with revenue decrease, Mytesi prescription volume changes, and promising POC results for rare diseases. FDA meeting on Phase 3 trial for breast cancer subgroup

Financial Results Jaguar Health Q1 2025 Mytesi Prescription POC Results
BRIEF

published on 05/14/2025 at 15:05, 10 months 4 days ago

Jaguar Health Schedules Investor Webcast for Q1 2025 Financials

Crofelemer Pharmaceuticals Investor Webcast Jaguar Health Q1 2025 Financials
PRESS RELEASE

published on 05/14/2025 at 15:00, 10 months 4 days ago

Jaguar Health to Hold Investor Webcast Thursday, May 15 at 4:15 PM Eastern Regarding Q1 2025 Financials & Corporate Updates
Jaguar Health, Inc. to file Q1 2025 Earnings Report on May 15, 2025 and conduct investor webcast. Focus on pharmaceuticals from rainforest plants for gastrointestinal distress

Pharmaceuticals Gastrointestinal Distress Earnings Report Investor Webcast Jaguar Health
BRIEF

published on 05/08/2025 at 15:35, 10 months 10 days ago

Jaguar Health Highlights Pet Cancer Awareness with Its Cancer Care Initiatives

Jaguar Health Chemotherapy Canalevia®-CA1 Pet Cancer Cancer Awareness
PRESS RELEASE

published on 05/08/2025 at 15:30, 10 months 10 days ago

Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs
Jaguar Health, Inc. celebrates FDA conditional approval of Canalevia®-CA1 prescription drug for chemotherapy-induced diarrhea in dogs, highlighting National Pet Cancer Awareness Month and supportive cancer care initiatives

FDA Approval Jaguar Health Canalevia-CA1 Chemotherapy-induced Diarrhea National Pet Cancer Awareness Month

Accesswire

Published on 03/19/2026 at 07:30, 2 hours 49 minutes ago

Tocvan Drone Magnetic Data Strengthens Gold-Silver Targets Across Gran Pilar; Identifies Broad Zones for Expansion Potential
Published on 03/19/2026 at 06:35, 3 hours 44 minutes ago

Golden Lake Announces Securityholder Approval of Arrangement with McEwen Inc.
Published on 03/19/2026 at 01:05, 9 hours 14 minutes ago

Prospect Ridge Announces Closing of Flow-Through Share Private Placement
Published on 03/18/2026 at 23:45, 10 hours 34 minutes ago

Orogen Royalties Announces Private Placement Update
Published on 03/18/2026 at 21:00, 13 hours 19 minutes ago

PLDT's Smart Selects Amdocs to Transform Retail Operations with AI-Powered Store Genie

View all ACCESSWIRE

EQS Group

Published on 03/19/2026 at 10:05, 14 minutes ago

Shipsy Launches AgentFleet, an AI Workforce for Logistics Operations
Published on 03/19/2026 at 10:05, 14 minutes ago

Villeroy & Boch successfully holds its own in the 2025 financial year despite challenging market conditions
Published on 03/19/2026 at 10:00, 18 minutes ago

Original-Research: Finexity AG (von GBC AG): BUY
Published on 03/19/2026 at 09:30, 49 minutes ago

DN Group AG: First International Impact Forum 2026 in Monaco focused on Circular & Blue Economy
Published on 03/19/2026 at 09:17, 1 hour 1 minute ago

Transaction in Own Shares

Les Echos

Published on 03/19/2026 at 08:45, 1 hour 34 minutes ago

Deezer and Sonos renew and expand long-term collaboration
Published on 03/19/2026 at 07:00, 3 hours 19 minutes ago

bioMérieux Receives IVDR CE‑Marking for Two BIOFIRE® SPOTFIRE® Panels to Strengthen Near‑Patient Respiratory and Sore Throat Diagnostics Across Europe
Published on 03/19/2026 at 07:00, 3 hours 19 minutes ago

2025 Annual results and new strategic signature
Published on 03/18/2026 at 19:41, 14 hours 38 minutes ago

Covivio - Conditions of availability of the 2025 Universal Registration Document
Published on 03/18/2026 at 18:00, 16 hours 19 minutes ago

Deezer achieves profitability in FY25 as strategy delivers tangible results

View all LES ECHOS COMFI WIRE